Document Detail

Sonographic appearance of the uterine cavity following administration of mifepristone and misoprostol for termination of pregnancy.
MedLine Citation:
PMID:  16788959     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To describe the sonographic appearance of the uterine cavity in women after administration of mifepristone and misoprostol for termination of pregnancy. METHODS: Thirty-six women treated with mifepristone 600 mg followed by misoprostol 400 mug 2 days later for termination of pregnancy were the subjects of the study. Gestational age as calculated from the last menstrual period was < or =49 days. Pretreatment sonographic parameters, including gestational sac size and crown-rump length, were measured. The sonographic appearance of the uterine cavity was recorded and documented 6 hours (T-1) and 14 days (T-2) after administration of misoprostol. RESULTS: The mean menstrual age of the patients was 42 days (range 31-49 days). The mean gestational age according to crown-rump length was 43 days (range 40-48 days). Sonographic examination performed atT-1 revealed 23 patients (62.9%) with a well-defined echogenic mass located in the uterine cavity, 2 patients (5.5%) with an intrauterine sac containing a nonviable embryo, and 11 patients (30.5%) with an endometrium thickness of 7-14 mm with no evidence of intrauterine contents. Doppler flow signals were detected in 15 of the 23 patients (65.2%) with an echogenic intrauterine mass. Sonographic examination performed at T-2 revealed 19 patients (52.8%) with a persistent echogenic intrauterine mass; Doppler flow could be detected in 15 of these patients (78.9%). Dilatation and curettage was required in 2 patients (5.6%) due to failure of treatment; all others regained normal menses. CONCLUSIONS: An intrauterine echogenic mass with well-defined borders, with or without Doppler flow signals, can be detected 2 weeks after administration of mifepristone and misoprostol for termination of pregnancy. Because most of the women in our study regained normal menses without further surgical intervention, this finding could indicate remnants of trophoblastic tissue evacuated spontaneously from the uterine cavity. Therefore, dilatation and curettage should be avoided in these cases, unless clinical symptoms or signs necessitate surgical intervention.
Ofer Markovitch; Ron Tepper; Zvi Klein; Ami Fishman; Rami Aviram
Related Documents :
9329649 - Monitoring of early human fetal development in women exposed to large doses of chemicals.
15539869 - Second- and third-trimester therapeutic terminations of pregnancy in cases with complet...
12420779 - Use of prostaglandins and bromocriptine mesylate for pregnancy termination in bitches.
990229 - Termination of abnormal intrauterine pregnancies with intramuscular administration of d...
17355269 - Termination of pregnancy for fetal anomaly: a population-based study 1995 to 2004.
12175439 - Sulprostone for pregnancy termination in women with severe (pre-) eclampsia.
489929 - 3,3',5'-triiodothyronine concentrations in amniotic fluid at different stages of pregna...
19012189 - Transport kinetics of cisplatin in the perfused human placental lobule in vitro.
21196709 - Diagnostic pitfall: pigmented lesion of the nipple - correlation between dermoscopy, re...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of clinical ultrasound : JCU     Volume:  34     ISSN:  0091-2751     ISO Abbreviation:  J Clin Ultrasound     Publication Date:    2006 Jul-Aug
Date Detail:
Created Date:  2006-06-26     Completed Date:  2006-11-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0401663     Medline TA:  J Clin Ultrasound     Country:  United States    
Other Details:
Languages:  eng     Pagination:  278-82     Citation Subset:  IM    
Copyright Information:
Copyright 2006 Wiley Periodicals, Inc.
Ultrasound Unit, Department of Obstetrics and Gynecology, Meir Medical Center, Tel Aviv University, Ramat Aviv, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Abortifacient Agents, Nonsteroidal / administration & dosage*
Abortifacient Agents, Steroidal / administration & dosage*
Abortion, Induced*
Mifepristone / administration & dosage*
Misoprostol / administration & dosage*
Pregnancy Trimester, First
Prospective Studies
Uterus / ultrasonography*
Reg. No./Substance:
0/Abortifacient Agents, Nonsteroidal; 0/Abortifacient Agents, Steroidal; 59122-46-2/Misoprostol; 84371-65-3/Mifepristone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Sonographic and mammographic findings of breast liquid silicone injection.
Next Document:  Role of hyperlipidemia in atherosclerotic plaque formation in the internal carotid artery.